ABIVAX Société Anonyme (NASDAQ:ABVX) Hits New 1-Year Low – Should You Sell?

ABIVAX Société Anonyme (NASDAQ:ABVX)’s stock price hit a new 52-week low during trading on Monday . The company traded as low as $8.17 and last traded at $8.17, with a volume of 1567 shares changing hands. The stock had previously closed at $8.53.

ABIVAX Société Anonyme Stock Performance

The business’s 50 day simple moving average is $10.00 and its 200 day simple moving average is $11.72.

Institutional Trading of ABIVAX Société Anonyme

Several large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its position in ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after purchasing an additional 5,900 shares during the period. Walleye Capital LLC boosted its holdings in shares of ABIVAX Société Anonyme by 45.8% during the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after buying an additional 80,807 shares during the period. Point72 Asset Management L.P. boosted its holdings in shares of ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after buying an additional 119,300 shares during the period. Finally, abrdn plc grew its stake in ABIVAX Société Anonyme by 167.7% in the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after buying an additional 198,225 shares during the last quarter. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.